Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chiara Cremolini

Showing results (181-190 of 284) with videos related to

Pageof 29
Sort By:
JCO Precision Oncology|May 11, 2022
Negative Ultraselection of Patients With <i>RAS</i>/<i>BRAF</i> Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti-EGFR-Based TherapyGiovanni Randon, Giulia Maddalena, Marco Maria Germani, et al.
European Journal of Cancer (Oxford, England : 1990)|November 4, 2023
Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LVFilippo Pietrantonio, Francesca Bergamo, Daniele Rossini, et al.
The New England Journal of Medicine|October 23, 2023
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated <i>KRAS</i> G12CMarwan G Fakih, Lisa Salvatore, Taito Esaki, et al.
British Journal of Cancer|March 14, 2018
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trialsChiara Cremolini, Massimo Milione, Federica Marmorino, et al.
Journal for Immunotherapy of Cancer|August 25, 2021
Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitorsFilippo Pietrantonio, Sara Lonardi, Francesca Corti, et al.
Molecular Cancer Therapeutics|May 20, 2016
Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus BevacizumabSatoshi Okazaki, Fotios Loupakis, Sebastian Stintzing, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 2022
Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancerCarlotta Antoniotti, Federica Marmorino, Alessandra Boccaccino, et al.
The New England Journal of Medicine|May 3, 2023
Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal CancerGerald W Prager, Julien Taieb, Marwan Fakih, et al.
British Journal of Cancer|August 28, 2025
Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trialsAlexej Ballhausen, Federica Morano, Arndt Stahler, et al.
The Oncologist|May 10, 2018
Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use ProgramChiara Cremolini, Daniele Rossini, Erika Martinelli, et al.
Pageof 29

Showing results (181-190 of 284) with videos related to

Sort By:
Pageof 29
JCO Precision Oncology|May 11, 2022
Negative Ultraselection of Patients With <i>RAS</i>/<i>BRAF</i> Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti-EGFR-Based TherapyGiovanni Randon, Giulia Maddalena, Marco Maria Germani, et al.
European Journal of Cancer (Oxford, England : 1990)|November 4, 2023
Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LVFilippo Pietrantonio, Francesca Bergamo, Daniele Rossini, et al.
The New England Journal of Medicine|October 23, 2023
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated <i>KRAS</i> G12CMarwan G Fakih, Lisa Salvatore, Taito Esaki, et al.
British Journal of Cancer|March 14, 2018
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trialsChiara Cremolini, Massimo Milione, Federica Marmorino, et al.
Journal for Immunotherapy of Cancer|August 25, 2021
Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitorsFilippo Pietrantonio, Sara Lonardi, Francesca Corti, et al.
Molecular Cancer Therapeutics|May 20, 2016
Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus BevacizumabSatoshi Okazaki, Fotios Loupakis, Sebastian Stintzing, et al.
European Journal of Cancer (Oxford, England : 1990)|March 1, 2022
Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancerCarlotta Antoniotti, Federica Marmorino, Alessandra Boccaccino, et al.
The New England Journal of Medicine|May 3, 2023
Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal CancerGerald W Prager, Julien Taieb, Marwan Fakih, et al.
British Journal of Cancer|August 28, 2025
Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trialsAlexej Ballhausen, Federica Morano, Arndt Stahler, et al.
The Oncologist|May 10, 2018
Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use ProgramChiara Cremolini, Daniele Rossini, Erika Martinelli, et al.
Pageof 29